Novo Holdings invests €500 million in Europe-focused fund as Alnylam advances second obesity drug to clinic
read at Endpoints ↗DealPositive
Novo Holdings, the investment arm of the Novo Nordisk Foundation, has committed €500 million to the Scaleup Europe Fund, a vehicle aimed at supporting European biotech scale‑ups.
Alnylam Pharmaceuticals announced that its second obesity‑targeting therapy has entered early‑stage clinical testing, marking a continued push into metabolic disease treatments.
The briefing also noted updates from IMU Biosciences, Autobahn, and Jade Biosciences, though details were not provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Novo Holdings backs European fund; Alnylam sends second obesity drug into clinic”
read at Endpoints ↗81 words · retrieved Jun 4
comments(0)
5-min edit window · permanent after that